Navigation Links
FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
Date:6/20/2012

SAN DIEGO, June 20, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting and presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium, in San Diego, June 22-24. FirstMark will showcase the groundbreaking research and data that is the foundation for PREvent. PREvent is the first and only multiple biomarker blood test on the market that accurately predicts near term (2-3 years) risk of myocardial infarction (MI) and death for coronary artery disease (CAD) patients. PREvent is an exciting development in cardiovascular patient management, addressing the unmet need to assess the risk of near term MI.

Dr. Sergey Sikora, Sr. Vice President of FirstMark, will present the research and data at the Symposium at 12:00 p.m. – 1:00  p.m., Sunday, June 24th, Paradise Point Resort at Mission Bay, Garden Room. Dr. Sikora is co-creator of a PREvent, along with noted cardiologists and researchers Dr. Arshed Quyyumi at Emory University, and Dr. Stephen Epstein at MedStar Health Research Institute. FirstMark will be exhibiting at the symposium on Friday, June 22nd, and Saturday, June 23rd.

"We look forward to the opportunity to present to the family physicians in attendance at the symposium," said Dr. Sikora. "The symposium focuses on novel technologies that determine patients at risk for particular medical conditions, in order to control or prevent further complications. This event provides a perfect setting for FirstMark to share the remarkable research data and benefits of PREvent. We believe many of the physicians that are in attendance will find PREvent of interest with strong potential for clinical application for their CAD patients."

PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annualized event rate of MI or death for 18.2% of significant CAD patients with all three biomarkers elevated as compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk patients.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit FirstMarkPREvent.com.

Media Contact: Deborah Moore FirstMark, 858-458-0866 x 113, dmoore@thefirstmark.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 

 


'/>"/>
SOURCE FirstMark
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
2. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
3. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
4. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
5. 2012 AAPS National Biotechnology Conference heads to San Diego
6. Harris Lewin elected to National Academy of Sciences
7. Professor known for work with hunter-gatherers elected to American Academy of Arts and Sciences
8. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
9. Family values
10. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
11. Starting a family does not encourage parents to eat healthier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology: